[go: up one dir, main page]

AU2001238677A1 - Method for preparing anti-mif antibodies - Google Patents

Method for preparing anti-mif antibodies

Info

Publication number
AU2001238677A1
AU2001238677A1 AU2001238677A AU3867701A AU2001238677A1 AU 2001238677 A1 AU2001238677 A1 AU 2001238677A1 AU 2001238677 A AU2001238677 A AU 2001238677A AU 3867701 A AU3867701 A AU 3867701A AU 2001238677 A1 AU2001238677 A1 AU 2001238677A1
Authority
AU
Australia
Prior art keywords
preparing anti
mif antibodies
mif
antibodies
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238677A
Inventor
Nabil Hanna
William S. Kloetzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of AU2001238677A1 publication Critical patent/AU2001238677A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
AU2001238677A 2000-02-28 2001-02-26 Method for preparing anti-mif antibodies Abandoned AU2001238677A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18539000P 2000-02-28 2000-02-28
US60185390 2000-02-28
US23362500P 2000-09-18 2000-09-18
US60233625 2000-09-18
PCT/US2001/005933 WO2001064749A2 (en) 2000-02-28 2001-02-26 Method for preparing anti-mif antibodies

Publications (1)

Publication Number Publication Date
AU2001238677A1 true AU2001238677A1 (en) 2001-09-12

Family

ID=26881101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238677A Abandoned AU2001238677A1 (en) 2000-02-28 2001-02-26 Method for preparing anti-mif antibodies

Country Status (3)

Country Link
US (2) US20030235584A1 (en)
AU (1) AU2001238677A1 (en)
WO (1) WO2001064749A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
DE19957065B4 (en) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening procedure for drugs
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US7361474B2 (en) * 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
JP5198848B2 (en) * 2004-03-29 2013-05-15 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ Treatment of type 1 diabetes using macrophage migration inhibitory factor inhibitor
US7555387B2 (en) 2005-01-28 2009-06-30 Orbitz, L.L.C. System and method for providing travel related product information on an interactive display having neighborhood categories
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
CN100457895C (en) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 Mouse Anti-Human Macrophage Migration Inhibitor Monoclonal Antibody and Its Application
CA2706732A1 (en) 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
NZ611117A (en) * 2008-01-04 2014-10-31 Baxter Int Anti mif antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
SI2609118T1 (en) 2010-08-23 2017-05-31 The Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
US9308255B2 (en) * 2010-11-24 2016-04-12 Yale University Methods of administering D-dopachrome tautomerase (D-DT) to treat ischemia-reperfusion injury
ES2865068T3 (en) 2011-01-14 2021-10-14 Univ California Therapeutic antibodies to ROR-1 protein and methods of using them
JP2014526886A (en) * 2011-07-15 2014-10-09 モルフォシス・アー・ゲー Antibodies cross-reactive with macrophage migration inhibitory factor (MIF) and D-dopachrome tomerase (D-DT)
JP2014530360A (en) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA OxMIF as a diagnostic marker
EP2753937B1 (en) * 2011-10-07 2018-01-17 Baxalta GmbH Characterization of cho-mif gene and protein, and use thereof
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
WO2013163758A1 (en) 2012-05-01 2013-11-07 Boyd Shelley Romayne Methods for treating and diagnosing blinding eye diseases
CN105452867A (en) 2012-07-10 2016-03-30 巴克斯特保健股份有限公司 Anti-mif immunohistochemistry
AU2013354035A1 (en) 2012-12-07 2015-06-11 Baxalta GmbH Anti-MIF antibody cell migration assay
RU2656153C1 (en) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Alpha-enolase specific antibodies and methods of uses in cancer therapy
US9382331B2 (en) 2013-12-27 2016-07-05 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
US10613100B2 (en) 2014-01-03 2020-04-07 Baxalta Incorporated Anti-MIF immunohistochemistry
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2016156489A1 (en) 2015-03-31 2016-10-06 Baxalta GmbH Dosage regimen for anti-mif antibodies
WO2016184886A1 (en) 2015-05-18 2016-11-24 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
TW201736399A (en) 2015-12-31 2017-10-16 財團法人生物技術開發中心 Anti-VEGFR antibody and uses thereof
CN109069628A (en) * 2016-01-14 2018-12-21 Bps生物科学有限公司 Anti- PD-1 antibody and application thereof
JP7437000B2 (en) 2016-07-01 2024-02-22 パラクライン セラピューティクス アーベー Methods and compositions for inhibition of PDGF-CC
EP3512880A1 (en) * 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR20200015921A (en) * 2017-07-03 2020-02-13 재단법인 생물기술개발중심 Anti-VEGFR Antibodies and Uses thereof
JP2021521173A (en) 2018-04-11 2021-08-26 オハイオ・ステイト・イノベーション・ファウンデーション Methods and compositions for sustained release microparticles for intraocular drug delivery
WO2019241430A2 (en) * 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672158B2 (en) * 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト Purified human macrophage migration inhibitory factor
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF

Also Published As

Publication number Publication date
US20060191024A1 (en) 2006-08-24
WO2001064749A3 (en) 2002-05-02
WO2001064749A2 (en) 2001-09-07
US20030235584A1 (en) 2003-12-25
US7294753B2 (en) 2007-11-13

Similar Documents

Publication Publication Date Title
AU2001238677A1 (en) Method for preparing anti-mif antibodies
AU2001252588A1 (en) Method for preparing microsphere
AU2002357049A1 (en) Methods for preparing 0-desmethylvenlafaxine
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001295611A1 (en) Multipressure method for producing ammonia
AU2001239243A1 (en) Method for producing nanosuspensions
AU2002231135A1 (en) Method for forming complex ceramic shapes
AU2001291882A1 (en) Method for producing polyisobutylphenols
AU2001278423A1 (en) Method for producing aldehydes
AU2406001A (en) Method for preparing glass-ceramic
AU2002214487A1 (en) Method for inducing apoptiosis
EP1298117A3 (en) Method for preparing bromofluorenes
AU2001231920A1 (en) Method for preparing alpha-halogenated ketones
AU2001268981A1 (en) Method for producing 2-chloro-5-chloromethyl-1,3-thiazole
HUP0301893A3 (en) Method for producing 2-chloro-5-chloromethyl-1,3-thiazole
AU2002222604A1 (en) Process for preparing substance GM-95
AU2002231187A1 (en) Method for synthesizing diamond
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2002212224A1 (en) Method for producing delta1-pyrrolines
AU4663601A (en) Method for preparing 9-deoxo-8a-aza-(8a-alkyl)-8a-homoerythromycin derivativesfrom 9-deoxo-9(z)-hydroxyiminoerythromycin
AU2001262147A1 (en) Method for producing 4-bromo- and 4-chloro-2-nitro-1-trifluoromethoxybenzene
AU2002241271A1 (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
AU2001272448A1 (en) Method for producing dna-arrays
HUP0401401A3 (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
AU2001295042A1 (en) Anti-stilbene antibodies